| Autor: |
Rathore AS; School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, India., Gupta KK; School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, India., Govindaraj SK; School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, India., Ajmani A; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India., Arivalagan J; Discovery Life Sciences, Malden, MA, USA., Anto RJ; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India., Kalishwaralal K; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India., Chandran SA; School of Chemical and Biotechnology, SASTRA Deemed to be University, Thanjavur, India. |
| Abstrakt: |
The Transcription factor II B (TFIIB)‑related factor 2 (BRF2) containing TFIIIB complex recruits RNA polymerase III multi-subunit complex to selective gene promoters that altogether are responsible for synthesizing a variety of small non-coding RNAs, including a special type of selenocysteine tRNA (tRNASec), micro-RNA (miRNA), and other regulatory RNAs. BRF2 has been identified as a potential oncogene that promotes cancer cell survival under oxidative stress through its genetic activation. The structure of the BRF2 protein was modeled using the Robetta server, refined, and validated using the Ramachandran plot. A virtual approach utilizing molecular docking was used to screen a natural compound library to determine potential compounds that can interact with the molecular pin motif of the BRF2 protein using Maestro (Schrodinger). Subsequent molecular dynamics simulation studies of the top four ligands that exhibited low glide scores were performed using GROMACS. The findings derived from the simulations, in conjunction with the exploration of hydrogen bonding patterns, evaluation of the free energy landscape, and thorough analysis of residue decomposition, collectively converged to emphasize the robust interaction characteristics exhibited by Ligand 366 (Deacetyl lanatoside C) and ligand 336 (Neogitogenin)-with the BRF2 protein. These natural compounds may be potential inhibitors of BRF2, which could modulate the regulation of selenoprotein synthesis in cancer cells. Targeting BRF2 using these promising compounds may offer a new therapeutic approach to sensitize cancer cells to ferroptosis and apoptosis.Communicated by Ramaswamy H. Sarma. |
